长春高新：子公司GenSci142胶囊国内生产药品注册临床试验申请获受理

Core Viewpoint - Changchun High-tech announced that its subsidiary, Changchun Jinsai Pharmaceutical Co., Ltd., has received the acceptance notice for the clinical trial application of GenSci142 capsules from the National Medical Products Administration [1] Group 1: Product Development - GenSci142 capsules are developed by Jinsai Pharmaceutical and target Gardnerella bacteria [1] - The product utilizes recombinant lytic enzymes selected through bioinformatics screening of phage sequences, which can directly disrupt bacterial cell walls, leading to rapid lysis and death of the bacteria [1]